---
title: "Telix Pharmaceuticals Limited (TLX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TLX.US.md"
symbol: "TLX.US"
name: "Telix Pharmaceuticals Limited"
industry: "Biotechnology"
---

# Telix Pharmaceuticals Limited (TLX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [elixpharma.com](https://elixpharma.com) |

## Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead thera...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:12.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 85 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 55.61% |  |
| Net Profit YoY | -121.15% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.84 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.43B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 803.79M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.85% | D |
| Profit Margin | -0.89% | D |
| Gross Margin | 47.51% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 55.61% | A |
| Net Profit YoY | -121.15% | E |
| Total Assets YoY | 23.78% | A |
| Net Assets YoY | 17.69% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -11281.32% | E |
| OCF YoY | 55.61% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.76 | B |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 64.31% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Telix Pharmaceuticals Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.85%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.89%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "47.51%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "55.61%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-121.15%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "23.78%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.69%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-11281.32%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "55.61%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "64.31%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -340.60 | 559/606 | 302.02 | 201.87 | 168.71 |
| PB | 5.84 | 320/606 | 15.98 | 8.78 | 6.63 |
| PS (TTM) | 3.02 | 70/606 | 10.96 | 5.58 | 4.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.25 |
| Highest Target | 22.48 |
| Lowest Target | 19.98 |

## References

- [Company Overview](https://longbridge.com/en/quote/TLX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TLX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TLX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.